A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics

Br J Nutr. 2002 Sep;88 Suppl 1:S67-72. doi: 10.1079/BJN2002631.


Irritable bowel syndrome (IBS) is a multi-factorial gastrointestinal condition affecting 8-22 % of the population with a higher prevalence in women and accounting for 20-50 % of referrals to gastroenterology clinics. It is characterised by abdominal pain, excessive flatus, variable bowel habit and abdominal bloating for which there is no evidence of detectable organic disease. Suggested aetiologies include gut motility and psychological disorders, psychophysiological phenomena and colonic malfermentation. The faecal microflora in IBS has been shown to be abnormal with higher numbers of facultative organisms and low numbers of lactobacilli and bifidobacteria. Although there is no evidence of food allergy in IBS, food intolerance has been identified and exclusion diets are beneficial to many IBS patients. Food intolerance may be due to abnormal fermentation of food residues in the colon, as a result of disruption of the normal flora. The role of probiotics in IBS has not been clearly defined. Some studies have shown improvements in pain and flatulence in response to probiotic administration, whilst others have shown no symptomatic improvement. It is possible that the future role of probiotics in IBS will lie in prevention, rather than cure.

Publication types

  • Review

MeSH terms

  • Colonic Diseases, Functional / diet therapy*
  • Colonic Diseases, Functional / microbiology*
  • Fermentation
  • Humans
  • Intestines / microbiology*
  • Probiotics / therapeutic use*